BR100 Increased By (0.57%)
BR30 Increased By (0.23%)
KSE100 Increased By (0.38%)
KSE30 Increased By (0.42%)
AGHA 7.80 Increased By ▲ 0.05 (0.65%)
BECO 5.21 Increased By ▲ 0.02 (0.39%)
BML 57.98 Decreased By ▼ -0.68 (-1.16%)
BOP 34.10 Increased By ▲ 0.41 (1.22%)
CNERGY 10.19 Decreased By ▼ -0.42 (-3.96%)
CSIL 5.40 Increased By ▲ 0.10 (1.89%)
FCCL 54.99 Increased By ▲ 1.25 (2.33%)
FFL 16.65 Increased By ▲ 0.19 (1.15%)
FNEL 1.25 Increased By ▲ 0.03 (2.46%)
KEL 7.38 Increased By ▲ 0.10 (1.37%)
KOSM 5.74 Increased By ▲ 0.10 (1.77%)
LOTCHEM 29.40 Decreased By ▼ -0.25 (-0.84%)
MLCF 95.11 Decreased By ▼ -1.25 (-1.3%)
NBP 204.00 Increased By ▲ 0.47 (0.23%)
NCPL 57.69 Increased By ▲ 0.84 (1.48%)
NPL 68.64 Increased By ▲ 1.33 (1.98%)
OGDC 317.48 Decreased By ▼ -0.74 (-0.23%)
PACE 10.69 Increased By ▲ 0.06 (0.56%)
PAEL 42.75 Increased By ▲ 0.98 (2.35%)
PIBTL 16.77 Decreased By ▼ -0.04 (-0.24%)
PPL 220.47 Increased By ▲ 0.30 (0.14%)
PRL 49.30 Increased By ▲ 0.25 (0.51%)
PTC 70.25 Increased By ▲ 0.24 (0.34%)
SSGC 28.40 Decreased By ▼ -0.74 (-2.54%)
TBL 9.84 Increased By ▲ 0.07 (0.72%)
TELE 8.85 Increased By ▲ 0.03 (0.34%)
TPL 18.03 Increased By ▲ 0.86 (5.01%)
TPLP 12.85 Increased By ▲ 0.34 (2.72%)
TREET 22.71 Increased By ▲ 0.12 (0.53%)
TRG 59.90 Decreased By ▼ -0.32 (-0.53%)
By

LONDON: British drugmaker AstraZeneca on Wednesday announced it would invest $400 million to plant over 200 million trees by 2030 as part of its strategy for reducing carbon emissions in line with the Paris Agreement.

The commitment represents about $60 million a year, for one of the UK’s most valuable listed companies, which has a market capitalization of about $230 billion.

AstraZeneca made about $44 billion in revenue in 2022. Still, the new sustainability commitment is far larger than past ones.

In 2020, the company announced it would plant and maintain more than 50 million trees by the end of 2025.

AstraZeneca announced earlier this month it would switch to biogas produced from cow manure and food waste in the US, to cut its carbon emissions there.

Much of the global pharmaceutical and biotech industry has yet to set targets for reducing carbon emissions in line with the Paris Agreement, researchers have found.

Comments

Comments are closed for this article.